UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Journal of managed care & specialty pharmacy, 2019-01, Vol.25 (1), p.46

2019

Volltextzugriff (PDF)

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Headache, 2018-09, Vol.58 (8), p.1225-1235

2018

Volltextzugriff (PDF)

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Journal of managed care & specialty pharmacy, 2018-09, Vol.24 (9), p.921

2018

Volltextzugriff (PDF)

Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine

Current medical research and opinion, 2018-04, Vol.34 (4), p.619-632

2018

Volltextzugriff (PDF)

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Headache, 2017-10, Vol.57 (9), p.1359-1374

2017

Volltextzugriff (PDF)

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

CNS neuroscience & therapeutics, 2016-12, Vol.22 (12), p.970-978

2016

Volltextzugriff (PDF)

Effects of Testosterone Level on Lower Urinary Tract Symptoms

American journal of men's health, 2016-09, Vol.10 (5), p.440-442

2016

Volltextzugriff (PDF)

Measurement of testosterone: how important is a morning blood draw?

Current Medical Research and Opinion, 2015, Vol.31 (10), p.1911-1914

2015

Volltextzugriff (PDF)

Measurement of testosterone: how important is a morning blood draw?

Current medical research and opinion, 2015-01, Vol.31 (10), p.1911-1914

2015

Volltextzugriff (PDF)

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Clinical schizophrenia & related psychoses, 2014-07, Vol.8 (2), p.84

2014

Volltextzugriff (PDF)

Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom

BMC geriatrics, 2014-06, Vol.14 (1), p.76-76, Article 76

2014

Volltextzugriff (PDF)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

Neuropsychiatric disease and treatment, 2013-01, Vol.9 (default), p.815-822

2013

Volltextzugriff (PDF)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

BMC medical research methodology, 2012-09, Vol.12 (1), p.142-142, Article 142

2012

Volltextzugriff (PDF)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

BMC psychiatry, 2011-09, Vol.11 (1), p.152-152, Article 152

2011

Volltextzugriff (PDF)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Patient preference and adherence, 2011-01, Vol.5 (default), p.547-554

2011

Volltextzugriff (PDF)

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Current medical research and opinion, 2010-10, Vol.26 (10), p.2403-2410

2010

Volltextzugriff (PDF)

Predictors of switching antipsychotic medications in the treatment of schizophrenia

BMC psychiatry, 2010-09, Vol.10 (1), p.75-75, Article 75

2010

Volltextzugriff (PDF)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

BMC psychiatry, 2010-01, Vol.10 (1), p.11-11, Article 11

2010

Volltextzugriff (PDF)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

BMC psychiatry, 2009-09, Vol.9 (1), p.54-54, Article 54

2009

Volltextzugriff (PDF)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Cost effectiveness and resource allocation, 2009-05, Vol.7 (11), p.11-11

2009

Volltextzugriff (PDF)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1163-1171

2008

Volltextzugriff (PDF)

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Current medical research and opinion, 2008-05, Vol.24 (5), p.1399-1405

2008

Volltextzugriff (PDF)

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Current Medical Research and Opinion, 2008, Vol.24 (5), p.1399-1405

2008

Volltextzugriff (PDF)

Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care

Journal of affective disorders, 2007-08, Vol.101 (1), p.187-193

2007

Volltextzugriff (PDF)

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Journal of clinical psychopharmacology, 2006-12, Vol.26 (6), p.666-667

2006

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(52)
Berichte
(2)

Sprache

Englisch
(54)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Humans
(41)
Male
(29)
Adult
(28)
Female
(28)
Middle Aged
(23)
Aged
(15)
Adolescent
(12)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Schizophrenia
(12)
Antipsychotic Agents - Therapeutic Use
(10)
Schizophrenia - Drug Therapy
(10)
Treatment Outcome
(9)
Indiana
(8)
Psychiatry
(8)
United States
(8)
Retrospective Studies
(7)
Cost-Benefit Analysis
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

Health Care Utilization and Direct Costs Among Patients Diagnosed with Cluster Headache in U.S. Health Care Claims Data

Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

Effects of Testosterone Level on Lower Urinary Tract Symptoms

Measurement of testosterone: how important is a morning blood draw?

Measurement of testosterone: how important is a morning blood draw?

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited

Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer's disease: a retrospective, matched case-control study in the United Kingdom

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

Predictors of switching antipsychotic medications in the treatment of schizophrenia

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Suchergebnisse filtern